<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01476163</url>
  </required_header>
  <id_info>
    <org_study_id>AT1001-188</org_study_id>
    <nct_id>NCT01476163</nct_id>
  </id_info>
  <brief_title>Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease</brief_title>
  <official_title>Physician Initiated Expanded Access Request for Treatment Use of Migalastat Hydrochloride (AT1001), an Investigational Treatment for Individual Patients With Fabry Disease (AT1001-188)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amicus Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amicus Therapeutics</source>
  <brief_summary>
    <textblock>
      This program allows physicians to request permission from Amicus Therapeutics (Amicus) for&#xD;
      treatment access to migalastat hydrochloride (HCl) for specific adult patients with Fabry&#xD;
      disease. Treatment is open label for 6 months with renewal every 6 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Physician Initiated Request program allows physicians to request permission from Amicus&#xD;
      to receive migalastat HCl for specific patients with Fabry disease who have a mutation&#xD;
      amenable to this treatment, who do not have access to available treatment alternatives, or do&#xD;
      not meet requirements for participation in an existing migalastat clinical study. Up to 20&#xD;
      patients worldwide may be treated. Patients must meet specific criteria to receive Amicus&#xD;
      permission for participation. Key criteria for participation include: 16-74 years old;&#xD;
      Confirmed GLA gene mutation shown to be responsive to migalastat; Have no treatment option&#xD;
      because either unsuitable for enzyme replacement therapy (ERT) or unable to access ERT.&#xD;
      Requirements for sufficient kidney function. If permission is granted, initial approval is&#xD;
      for a 6 month supply of migalastat HCl with renewal every 6 months available upon meeting&#xD;
      continued eligibility.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Approved for marketing</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Fabry Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>migalastat HCl</intervention_name>
    <description>150 mg capsule taken every other day by mouth. An inactive reminder capsule may be provided to take on the days in between migalastat HCl</description>
    <other_name>AT1001, migalastat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed GLA mutation predicted to be responsive migalastat in the human embryonic&#xD;
             kidney (HEK-293) cell-based assay&#xD;
&#xD;
          -  16-74 years of age&#xD;
&#xD;
          -  Strong clinical indication for treatment of Fabry disease&#xD;
&#xD;
          -  No other treatment option including either unsuitable for ERT or unable to access ERT&#xD;
&#xD;
          -  Appropriate female and male contraception&#xD;
&#xD;
          -  Willing to receive treatment with migalastat HCl via this program including having&#xD;
             signed an authorization for sharing clinical data&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) or GFR &lt;30 mL/minute&#xD;
&#xD;
          -  Scheduled for renal or other organ transplant or replacement therapy&#xD;
&#xD;
          -  Receiving GLYSET® (miglitol), ZAVESCA® (miglustat) or enzyme replacement therapy&#xD;
             FABRAZYME® (agalsidase beta) or REPLAGAL™ (agalsidase alpha)&#xD;
&#xD;
          -  Contraindication to migalastat, i.e., sensitivity to other iminosugar such as&#xD;
             miglustat, miglitol&#xD;
&#xD;
          -  Treated with another investigational drug within 30 days of start of migalastat HCl&#xD;
             treatment&#xD;
&#xD;
          -  Unable to comply with study requirements or deemed otherwise unsuitable for study&#xD;
             entry in the opinion of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor, Clinical Research</last_name>
    <role>Study Director</role>
    <affiliation>Amicus Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHOC Children's Hospital Division of Metabolic Disease</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kidney Care and Transplant Services of New England</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>November 17, 2011</study_first_submitted>
  <study_first_submitted_qc>November 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2011</study_first_posted>
  <last_update_submitted>January 22, 2019</last_update_submitted>
  <last_update_submitted_qc>January 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AT1001</keyword>
  <keyword>Lysosomal storage disease</keyword>
  <keyword>Lysosomal Storage Disorder</keyword>
  <keyword>migalastat</keyword>
  <keyword>Fabry disease</keyword>
  <keyword>Fabry</keyword>
  <keyword>Amicus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

